US Parkinson's Disease Drug Pipeline Analysis
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Parkinson’s disease incidence has been on a rise in the United States in recent years and it most likely to continue rising in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. The society pays a significant amount towards treating this disease in the country. It is estimated that the total cost to the nation exceeds USD 20 billion annually. The risk of this disease increases with age, thus implying that as the population in the US gets older, the impact of this disease on the financial and public health would also increase. Approximately 60,000 Americans are diagnosed with Parkinson's disease each year, and this number does not reflect the thousands of cases that go undetected.
“US Parkinson’s Disease Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Parkinson’s disease in US. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Parkinson’s disease drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Parkinson’s Disease Drug Pipeline Analysis” research report:
Parkinson’s disease incidence has been on a rise in the United States in recent years and it most likely to continue rising in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. The society pays a significant amount towards treating this disease in the country. It is estimated that the total cost to the nation exceeds USD 20 billion annually. The risk of this disease increases with age, thus implying that as the population in the US gets older, the impact of this disease on the financial and public health would also increase. Approximately 60,000 Americans are diagnosed with Parkinson's disease each year, and this number does not reflect the thousands of cases that go undetected.
“US Parkinson’s Disease Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Parkinson’s disease in US. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Parkinson’s disease drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Parkinson’s Disease Drug Pipeline Analysis” research report:
- Drug Profile Overview
- Alternate Names for Drug
- Active Indication
- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes
- Research: 16
- Preclinical: 57
- Phase-I: 8
- Phase-I/II: 3
- Phase-II: 13
- Phase-II/III: 1
- Phase-III: 2
- Preregistration: 3
- Registered:1
- Marketed: 9
1. US PARKINSON'S DRUG MARKET OVERVIEW
2. PARKINSON’S DRUG CLINICAL PHASE: RESEARCH
2.1 Overview
2.2 Parkinson’s Drug Profile in Clinical Phase
3. PARKINSON’S DRUG CLINICAL PHASE: PRECLINICAL
3.1 Overview
3.2 Parkinson’s Drug Profile in Clinical Phase
4. PARKINSON’S DRUG CLINICAL PHASE: PHASE-I
4.1 Overview
4.2 Parkinson’s Drug Profile in Clinical Phase
5. PARKINSON’S DRUG CLINICAL PHASE: PHASE-I/II
5.1 Overview
5.2 Parkinson’s Drug Profile in Clinical Phase
6. PARKINSON’S DRUG CLINICAL PHASE: PHASE-II
6.1 Overview
6.2 Parkinson’s Drug Profile in Clinical Phase
7. PARKINSON’S DRUG CLINICAL PHASE: PHASE-II/III
7.1 Overview
7.2 Parkinson’s Drug Profile in Clinical Phase
8. PARKINSON’S DRUG CLINICAL PHASE: PHASE-III
8.1 Overview
8.2 Parkinson’s Drug Profile in Clinical Phase
9. DRUG PARKINSON’S DRUG CLINICAL PHASE: PREREGISTRATION
9.1 Overview
9.2 Parkinson’s Drug Profile in Clinical Phase
10. DRUG PARKINSON’S DRUG CLINICAL PHASE: REGISTERED
10.1 Overview
10.2 Parkinson’s Drug Profile in Clinical Phase
11. MARKETED
11.1 Overview
11.2 Marketed Parkinson’s Drug Profile
2. PARKINSON’S DRUG CLINICAL PHASE: RESEARCH
2.1 Overview
2.2 Parkinson’s Drug Profile in Clinical Phase
3. PARKINSON’S DRUG CLINICAL PHASE: PRECLINICAL
3.1 Overview
3.2 Parkinson’s Drug Profile in Clinical Phase
4. PARKINSON’S DRUG CLINICAL PHASE: PHASE-I
4.1 Overview
4.2 Parkinson’s Drug Profile in Clinical Phase
5. PARKINSON’S DRUG CLINICAL PHASE: PHASE-I/II
5.1 Overview
5.2 Parkinson’s Drug Profile in Clinical Phase
6. PARKINSON’S DRUG CLINICAL PHASE: PHASE-II
6.1 Overview
6.2 Parkinson’s Drug Profile in Clinical Phase
7. PARKINSON’S DRUG CLINICAL PHASE: PHASE-II/III
7.1 Overview
7.2 Parkinson’s Drug Profile in Clinical Phase
8. PARKINSON’S DRUG CLINICAL PHASE: PHASE-III
8.1 Overview
8.2 Parkinson’s Drug Profile in Clinical Phase
9. DRUG PARKINSON’S DRUG CLINICAL PHASE: PREREGISTRATION
9.1 Overview
9.2 Parkinson’s Drug Profile in Clinical Phase
10. DRUG PARKINSON’S DRUG CLINICAL PHASE: REGISTERED
10.1 Overview
10.2 Parkinson’s Drug Profile in Clinical Phase
11. MARKETED
11.1 Overview
11.2 Marketed Parkinson’s Drug Profile
